home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

A New Treatment for Arrhythmia

  April, 3 2009 2:55
your information resource in human molecular genetics

A drug currently available in the clinic could be used to treat patients with an inherited form of cardiac arrhythmia, according to a study published in Nature Medicine.

CPVT -- a specific type of ventricular tachycardia -- is a potentially lethal form of arrhythmia. It is commonly linked to mutations in cardiac calcium channels known as ryanodine receptors. Pharmacological interventions against CPVT are often ineffective, but Björn Knollmann and his colleagues have now found that flecainide -- a drug already approved to treat other arrhythmias by acting on sodium channels -- prevents disease in a mouse model of CPVT by a new mechanism: the direct inhibition of calcium release mediated by cardiac ryanodine receptors.

Flecainide also prevented CPVT in two patients who had not responded to conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy against this condition.

Author contact:

Björn Knollmann (Vanderbilt University, Nashville, TN, USA)
E-mail: bjorn.knollmann@vanderbilt.edu

Abstract available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.